Ohsu Knight Cancer Institute
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05457478
- Locations
- ๐บ๐ธ
Mid-Atlantic Permanente Medical Group, Rockville, Maryland, United States
๐บ๐ธOHSU Knight Cancer Institute, Portland, Oregon, United States
A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT05453851
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 300
- Registration Number
- NCT05407168
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
๐บ๐ธHillsboro Medical Center, Hillsboro, Oregon, United States
๐บ๐ธAdventist Health Portland, Portland, Oregon, United States
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT05396859
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
Early Phase 1
Withdrawn
- Conditions
- Advanced Fallopian Tube CarcinomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaStage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05368506
Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate
Not Applicable
Suspended
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05362032
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05327738
At-Home Dermoscopy Artificial Intelligence
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 310
- Registration Number
- NCT05321784
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
SMMART Adaptive Clinical Treatment (ACT) Trial
Early Phase 1
Withdrawn
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Y-90 Versus SBRT for Inoperable HCC
Phase 2
Withdrawn
- Conditions
- Stage I Hepatocellular Carcinoma AJCC v8Stage IA Hepatocellular Carcinoma AJCC v8Stage IB Hepatocellular Carcinoma AJCC v8Hepatocellular CarcinomaStage II Hepatocellular Carcinoma AJCC v8Stage III Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05157451
ยฉ Copyright 2024. All Rights Reserved by MedPath